tirzepatide eu approval regulator recommends Eli Lilly's Mounjaro for weight management Eli Lilly Gets FDA Approval

Medical history, current medications, diabetes status, heart health, kidney health, stomach problems, insurance coverage, and weight goals all matter

GLP-1 Market Size: USD 68.65 billion in 2026 | USD 195.01 billion by 2035 | CAGR: 12.3% | Leading Molecule: Semaglutide ( 52.1% revenue share) | Dominant Region: United States ( 62.8% revenue share) GLP-1 Weight Loss Drug Market Highlights: Key Data at a Glance ( 2026 ) GLP-1 Weight Loss Drug Market Size 2026 : USD 68.65 billion , forecast USD 195.01 billion by 2035 at 12.3% CAGR Dominant drug class: Dual GIP/GLP-1 Agonists (tirzepatide) and Injectable GLP-1 RA Monoagonists (semaglutide) with 78.4% combined revenue share Fastest-growing route: Oral GLP-1 formulations at 34.2% CAGR through 2035 driven by injection-free patient access expansion GLP-1 market leaders: Novo Nordisk and Eli Lilly with approximately 87% combined prescription weight management drug revenue share in 2026 Most prescribed weight loss molecule: Semaglutide (Wegovy and Ozempic) with 52.1% global GLP-1 market revenue share in 2026 FDA-approved anti-obesity GLP-1 drugs: Four molecules including semaglutide, tirzepatide, liraglutide, and oral semaglutide as of 2026 Global obesity patient pool: More than 1.1 billion adults with obesity globally

While tirzepatide may be associated with hair loss as reported in clinical trials, the substantial weight loss it produces can trigger a well-recognized condition called telogen effluvium

For further context, a person weighing 250 pounds could expect to lose between 37 to 50 pounds

It is important to distinguish between causation and correlation when patients report new symptoms during treatment

In one study, more than half the participants (54%) had no previous use of oral glucose-lowering medication [22], while in another study, all participants were on a stable dose of insulin glargine with (83%) or without (17%) metformin [19]